Genetic ablation of complement C3 attenuates muscle pathology in dysferlin-deficient mice

Renzhi Han1, Ellie M Frett, Jennifer R Levy

  • 1Howard Hughes Medical Institute, Department of Molecular Physiology and Biophysics, Department of Neurology, Department of Internal Medicine, Roy J. and Lucille A. Carver College of Medicine, The University of Iowa, Iowa City, Iowa, USA.

Insights

Dysferlin deficiency causes muscle wasting by activating the complement system. Targeting this system ameliorates muscle pathology in dysferlinopathy, offering a potential therapeutic strategy.

Area of Science:

  • Muscle biology
  • Immunology
  • Genetics

Background:

  • Mutations in the dysferlin gene cause dysferlinopathies, a group of muscle-wasting disorders.
  • Dysferlin is crucial for muscle membrane repair and regeneration, involving vesicle-membrane fusion.
  • The immune system's role in dysferlinopathy pathogenesis is not fully understood.

Purpose of the Study:

  • To investigate the role of the complement system in the muscle pathology of dysferlinopathies.
  • To explore the potential of targeting the complement system as a therapeutic strategy for dysferlinopathy.

Main Methods:

  • Analyzing complement factor expression in dysferlin-deficient mice.
  • Examining the effects of muscle-specific dysferlin expression on complement factors and muscle phenotype.
  • Assessing the impact of complement component 3 (C3) disruption on muscle pathology in dysferlin-deficient and mdx mice.

Main Results:

  • Dysferlin deficiency led to increased complement factor expression in muscles.
  • Restoring dysferlin expression normalized complement factors and resolved the dystrophic phenotype in mice.
  • Genetic disruption of C3 ameliorated muscle pathology in dysferlin-deficient mice but not in mdx mice.

Conclusions:

  • Complement-mediated muscle injury is central to dysferlinopathy pathogenesis.
  • Targeting the complement system represents a promising therapeutic avenue for dysferlinopathies.